Equillium (EQ) Non-Current Assets (2017 - 2026)
Equillium (EQ) posted quarterly Non-Current Assets of $808000.0 for Q1 2026, up 57.5% year-over-year from $513000.0 in Q1 2025, and down 4.83% quarter-over-quarter from $849000.0 in Q4 2025.
Equillium (EQ) Non-Current Assets (2017 - 2026) Analysis & Trends
Equillium (EQ) has reported Non-Current Assets for 10 consecutive years, with $808000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 57.5% year-over-year to $808000.0; the TTM figure through Mar 2026 stood at $3.0 million (up 3.66% YoY), while the FY2025 annual figure was $849000.0, up 35.62% from the prior year.
- Non-Current Assets slipped to $808000.0 in Q1 2026 per EQ's latest filing, from $849000.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $1.9 million in Q3 2022 and bottomed at -$53.7 million in Q4 2022.
- Historically, Non-Current Assets has averaged -$7.4 million across 5 years, with a median of $849000.0 in 2025.
- On a YoY basis, Non-Current Assets climbed as much as 518.33% in 2022 and fell as far as 22089.24% in 2022.
- Equillium's Non-Current Assets stood at -$53.7 million in 2022, then soared by 102.2% to $1.2 million in 2023, then tumbled by 46.99% to $626000.0 in 2024, then jumped by 35.62% to $849000.0 in 2025, then slipped by 4.83% to $808000.0 in 2026.
- Business Quant data shows EQ's Non-Current Assets at $808000.0 in Q1 2026, $849000.0 in Q4 2025, and $927000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Equillium | 263.86 Mn | 263.86 Mn | - | 690,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 690,000.00 |
| Mar 31, 2026 | 808,000.00 |
| Dec 31, 2025 | 849,000.00 |
| Sep 30, 2025 | 927,000.00 |
| Jun 30, 2025 | 447,000.00 |
| Mar 31, 2025 | 513,000.00 |
| Dec 31, 2024 | 626,000.00 |
| Sep 30, 2024 | 811,000.00 |
| Jun 30, 2024 | 974,000.00 |
| Mar 31, 2024 | 1.12 Mn |
| Dec 31, 2023 | 1.18 Mn |
| Sep 30, 2023 | 1.31 Mn |
| Jun 30, 2023 | 1.41 Mn |
| Mar 31, 2023 | 1.57 Mn |
| Dec 31, 2022 | -53.69 Mn |
| Sep 30, 2022 | 1.86 Mn |
| Jun 30, 2022 | -37.43 Mn |
| Mar 31, 2022 | -49.04 Mn |
| Dec 31, 2021 | 2.04 Mn |
| Sep 30, 2021 | 300,000.00 |